Therapeutic modulation of prostate cancer metastasis

被引:7
|
作者
Krishna, Sankar N. [1 ]
Bergan, Raymond C. [1 ,2 ,3 ]
机构
[1] Northwestern Univ, Dept Med, Feinberg Sch Med, Div Hematol Oncol, Chicago, IL 60611 USA
[2] Northwestern Univ, Ctr Mol Innovat & Drug Discovery, Feinberg Sch Med, Chicago, IL 60611 USA
[3] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Feinberg Sch Med, Chicago, IL 60611 USA
关键词
CIRCULATING TUMOR-CELLS; HUMAN MONOCLONAL-ANTIBODY; ENDOTHELIAL GROWTH-FACTOR; I KINASE INHIBITOR; TGF-BETA; PHASE-I; OSTEOCLAST DIFFERENTIATION; MATRIX METALLOPROTEINASES; SIGNALING PATHWAY; ZOLEDRONIC ACID;
D O I
10.4155/fmc.13.201
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Targeting prostate cancer metastasis has very high therapeutic potential. Prostate cancer is the second most common cause of cancer death among men in the USA, and death results from the development of metastatic disease. In order to metastasize, cancer cells must complete a series of steps that together constitute the metastatic cascade. Each step therefore offers the opportunity for therapeutic targeting. However, practical limitations have served as limiting roadblocks to successfully targeting the metastatic cascade. They include our still-emerging understanding of the underlying biology, as well as the fact that many of the dysregulated processes have critical functionality in otherwise normal cells. We provide a discussion of the underlying biology, as it relates to therapeutic targeting. Therapeutic inroads are rapidly being made, and we present a series of case studies to highlight key points. Finally, future perspectives related to drug discovery for antimetastatic agents are discussed.
引用
收藏
页码:223 / 239
页数:17
相关论文
共 50 条
  • [1] Therapeutic implications of autophagy modulation in prostate cancer
    C. Giampietri
    S. Petrungaro
    A. Facchiano
    A. Filippini
    E. Ziparo
    Journal of Endocrinological Investigation, 2012, 35 : 945 - 945
  • [2] Therapeutic implications of autophagy modulation in prostate cancer
    Giampietri, C.
    Petrungaro, S.
    Facchiano, A.
    Filippini, A.
    Ziparo, E.
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2012, 35 (10) : 945 - 945
  • [3] Therapeutic management of bone metastasis in prostate cancer: an update
    Zustovich, Fable
    Pastorelli, Davide
    EXPERT REVIEW OF ANTICANCER THERAPY, 2016, 16 (11) : 1199 - 1211
  • [4] Bone metastasis in prostate cancer: emerging therapeutic strategies
    Sturge, Justin
    Caley, Matthew P.
    Waxman, Jonathan
    NATURE REVIEWS CLINICAL ONCOLOGY, 2011, 8 (06) : 357 - 368
  • [5] Metastasis as a therapeutic target in prostate cancer: a conceptual framework
    Stoletov, Konstantin
    Bond, David
    Hebron, Katie
    Raha, Srijan
    Zijlstra, Andries
    Lewis, John D.
    AMERICAN JOURNAL OF CLINICAL AND EXPERIMENTAL UROLOGY, 2014, 2 (01): : 45 - 56
  • [6] Bone metastasis in prostate cancer: emerging therapeutic strategies
    Justin Sturge
    Matthew P. Caley
    Jonathan Waxman
    Nature Reviews Clinical Oncology, 2011, 8 : 357 - 368
  • [7] Inflammation as a Driver of Prostate Cancer Metastasis and Therapeutic Resistance
    Archer, Maddison
    Dogra, Navneet
    Kyprianou, Natasha
    CANCERS, 2020, 12 (10) : 1 - 24
  • [8] Derivation of MPR and TRAMP models of prostate cancer and prostate cancer metastasis for evaluation of therapeutic strategies
    Voeks, DJ
    Martiniello-Wilks, R
    Russell, PJ
    UROLOGIC ONCOLOGY, 2002, 7 (03): : 111 - 118
  • [9] Transcriptional dissection and therapeutic modulation of metastasis development in pancreatic cancer
    Lopez-Casas, Pedro P.
    Dimitrov, Spas
    Perales-Paton, Javier
    Banos, Natalia
    Munoz, Manuel
    Dopazo, Ana
    Al-Shahrour, Fatima
    Hidalgo, Manuel
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
  • [10] Correction: Bone metastasis in prostate cancer: emerging therapeutic strategies
    Justin Sturge
    Matthew P. Caley
    Jonathan Waxman
    Nature Reviews Clinical Oncology, 2011, 8 : 568 - 568